Patents Examined by Li Lee
-
Patent number: 8680052Abstract: Methods of treating, reducing the incidence of, and/or preventing an ischemic event in a patient undergoing percutaneous coronary intervention (PCI), comprising administering to the patient a pharmaceutical composition comprising cangrelor. The method may further comprise administering an additional therapeutic agent to the patient, the additional therapeutic agent comprising a P2Y12 inhibitor. Pharmaceutical compositions useful for treating, reducing the incidence of, and/or preventing an ischemic event in a patient undergoing PCI. The pharmaceutical compositions comprise cangrelor. Methods of preparing a pharmaceutical composition for treating, reducing the incidence of, and/or preventing an ischemic event in a patient undergoing PCI, comprising admixing cangrelor with one or more pharmaceutically acceptable excipients. An ischemic event may include stent thrombosis, myocardial infarction, ischemia-driven revascularization, and mortality.Type: GrantFiled: May 29, 2013Date of Patent: March 25, 2014Assignee: The Medicines CompanyInventors: Clive Arthur Arculus-Meanwell, Simona Skerjanec, Jayne Prats, David J. Schneider
-
Patent number: 8669229Abstract: The present invention provides a benzazepine compound that can maintain for a long period of time the blood level of tolvaptan enabling to provide the desired pharmaceutical effects. The benzazepine compound of the present invention is represented by general formula (1) wherein R1 represents a —CO—(CH2)n—COR2 group (wherein n is an integer of 1 to 4, and R2 is (2-1) a hydroxy group; (2-2) a lower alkoxy group optionally substituted with a hydroxy group, a lower alkanoyl group, a lower alkanoyloxy group, a lower alkoxycarbonyloxy group, a cycloalkyloxycarbonyloxy group, or 5-methyl-2-oxo-1,3-dioxo-4-yl; or (2-3) an amino group optionally substituted with a hydroxy-lower alkyl group), or the like.Type: GrantFiled: June 26, 2008Date of Patent: March 11, 2014Assignee: Otsuka Pharmaceutical Co., Ltd.Inventors: Kazumi Kondo, Yasuhiro Menjo, Takahiro Tomoyasu, Shin Miyamura, Yuso Tomohira, Takakuni Matsuda, Keigo Yamada, Yusuke Kato
-
Patent number: 8648046Abstract: The present invention relates generally to the field of cancer diagnosis and treatment, and more particularly to compositions and methods that may be useful for eliminating cancer cells with stem-like characteristics. The disclosed compositions and methods may also be useful for managing breast cancer, ovarian cancer, cervical cancer or endometrial (uterine) cancer with metastases; and visualizing the cancer cells in patient's body. The compositions of the instant invention include human prolactin receptor antagonist G129R.Type: GrantFiled: November 17, 2010Date of Patent: February 11, 2014Assignee: Oncolix, Inc.Inventor: Wen Y. Chen
-
Patent number: 8642512Abstract: Provided are methods of diagnosing an early immune activation by detecting T-cell immune response cDNA 7 (TIRC7); in particular, TIRC7 as an early biomarker for the detection of transplant rejection in a non-invasive diagnostic methods is described that replaces biopsy intervention with a simple diagnostic method for monitoring after transplantation and furthermore, kits for uses in such methods of diagnosis are provided.Type: GrantFiled: May 17, 2006Date of Patent: February 4, 2014Assignee: Cellact Pharma GmbHInventor: Nalân Utku
-
Patent number: 8642513Abstract: The invention relates to the generation of immunoglobulin libraries and the identification and production of immunoglobulins having a specific functionality of interest.Type: GrantFiled: September 14, 2006Date of Patent: February 4, 2014Assignee: Crucell Holland B.V.Inventors: Mark Throsby, Cornelis Adriaan De Kruif, Adrianus Quirinus Bakker
-
Patent number: 8623818Abstract: The present invention relates to compounds of general formula (I), wherein ring A, ring B, R1, R2, R3, Z, and L1 are selected independently of each other and are as defined herein, to compositions comprising the compounds, and methods of using the compounds as glucagon receptor antagonists and for the treatment or prevention of type 2 diabetes and conditions related thereto.Type: GrantFiled: May 13, 2009Date of Patent: January 7, 2014Assignee: Merck Sharp & Dohme Corp.Inventors: William J. Greenlee, Andrew Stamford, Michael W. Miller, Duane Eugene DeMong
-
Patent number: 8617624Abstract: Methods and systems for detecting azetidine-2-carboxylic acid (Aze) in food consumable by humans and animals are provided. Also provided are methods and systems for inactivating Aze in food and byproducts, as well as other methods for the diagnosis, prevention, and treatment of disorders associated with Aze.Type: GrantFiled: November 10, 2010Date of Patent: December 31, 2013Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventor: Edward Rubenstein
-
Patent number: 8609609Abstract: Host RNA/viral protein interaction as a target of intervention in the replication of viruses, e.g., the human immunodeficiency virus (HIV) are described. The target being upstream of the final replication product, and being crucial to the viral replication, is less likely to be genetically altered to drug resistance. Peptides that intervene in this RNA/viral protein interaction are also described, as well as compositions containing the same and methods of use thereof.Type: GrantFiled: January 16, 2009Date of Patent: December 17, 2013Assignee: North Carolina State UniversityInventor: Paul F. Agris
-
Patent number: 8598316Abstract: The present invention provides a conjugate that contains a therapeutic moiety linked to a homing peptide or peptidomimetic which selectively homes to vasculature of pre-malignant dysplastic skin and which includes the amino acid sequence SRPRR (SEQ ID NO: 1) or a conservative variant or peptidomimetic thereof. The present invention further provides a conjugate containing a therapeutic moiety linked to a homing peptide or peptidomimetic which selectively homes to vasculature of malignant skin and which includes the amino acid sequence CGKRK (SEQ ID NO: 6) or the amino acid sequence CDTRL (SEQ ID NO: 7), or a conservative variant or peptidomimetic of one of these sequences.Type: GrantFiled: March 26, 2010Date of Patent: December 3, 2013Assignees: Sanford-Burnham Medical Research Institute, The Regents of the University of CaliforniaInventors: Douglas Hanahan, Erkki Ruoslahti
-
Patent number: 8592551Abstract: Discrete and diffuse defects in a surface are detected. Discrete defects that may compromise the performance may be repaired.Type: GrantFiled: October 19, 2005Date of Patent: November 26, 2013Assignee: Massachusetts Institute of TechnologyInventors: Asher K. Sinensky, Angela M. Belcher
-
Patent number: 8586544Abstract: The present invention relates to a cell-permeable endostatin recombinant protein in which a macromolecule transduction domain (MTD) is fused to an angiogenesis inhibitor (angiogenesis inhibitor) endostatin; a polynucleotide encoding the cell-permeable endostatin recombinant protein; an expression vector for the cell-permeable endostatin recombinant protein; and a pharmacological composition for an anti-cancer preparation with improved inhibitory activity against angiogenesis in cancer, which contains the cell-permeable endostatin recombinant protein as an active component.Type: GrantFiled: April 3, 2009Date of Patent: November 19, 2013Assignees: Procell Therapeutics Inc.Inventors: Daewoong Jo, Jong Min Lee, Kyoungho Park, Minh Tam Duong
-
Patent number: 8575096Abstract: The invention is related to fast acting insulin analogues which can form soluble mix-tures (pre-mixed or self-mixed) with long acting insulin analogues. The fast action is achieved through monomerizing substitutions/deletions in the C-terminus of the B-chain of human insulin and the mixability with long acting insulin analogues is achieved through a substitution of the Zn-binding His in position B10 of human insulin with a Gln amino acid residue. In one embodiment the invention is related to fast acting insulin analogues in which at least one of the natural amino acid residues in position B22-B30 in the human B-chain has been substituted with another amino acid residue having the effect of promoting formation of the monomeric form of insulin, the His amino acid residue in position 10 in the B-chain is substituted with a Gln and wherein further one or more of the amino acid residues in position B22-B30 optionally have been deleted.Type: GrantFiled: August 12, 2008Date of Patent: November 5, 2013Assignee: Novo Nordisk A/SInventors: Helle Birk Olsen, Thomas Børglum Kjeldsen, Per Balschmidt, Tine Glendorf, Svend Havelund
-
Patent number: 8569226Abstract: A dodecamer peptide, and its modified variant, having a repeating glycine-lysine sequence was created and found to bind with high affinity to oxide surfaces and certain activated polymeric surfaces. Reversible binding characteristics of the peptides were demonstrated. The peptides were integrated with proteins, cells and fusion proteins to provide attachment of the proteins, cells and fusion proteins to solid material structures. The peptides can be used to functionalize surfaces of components within mechanical, in mechanical, biomechanical, micro fluidic, electronic, bioelectronic, bio-optical, and biochemical devices. Experiments were carried out to assess functionalization and reusability of a suspended mass resonator's cantilever.Type: GrantFiled: September 19, 2008Date of Patent: October 29, 2013Assignee: Massachusetts Institute of TechnologyInventors: Eric Mark Krauland, Stephen Kottmann, Roberto Juan Barbero, Angela Belcher
-
Patent number: 8563683Abstract: The present invention relates to synthetic lung surfactant compositions that contain one or more of phospholipase-resistant phospho-glycerol derivatives, phospholipase-resistant phospho-choline derivatives, and surface active proteins or peptides, more preferably a combination of at least two or all three of these materials. Novel phospholipase-resistant phospho-glycerol derivatives, phospholipase-resistant phospho-choline derivatives, and surface active peptides are also disclosed herein. Uses of the surfactant compositions of the present invention to treat endogenous surfactant dysfunctional or deficient lung tissue, to prepare synthetic peptides for use in the surfactant compositions, and to deliver therapeutic agents are also disclosed.Type: GrantFiled: July 20, 2007Date of Patent: October 22, 2013Assignees: University of Rochester, The Los Angeles BioMedical Research Institute at Harbor—UCLA Medical Center, University of GuelphInventors: Robert H. Notter, Zhengdong Wang, Adrian L. Schwan, Zhongyi Wang, Jason A. Davy, Alan J. Waring, Frans J. Walther, Larry M. Gordon
-
Patent number: 8551938Abstract: Disclosed are novel compounds having NPR-B agonistic activity. Preferred compounds are linear peptides containing 8-13 conventional or non-conventional L- or D-amino acid residues connected to one another via peptide bonds.Type: GrantFiled: September 23, 2010Date of Patent: October 8, 2013Assignee: Alcon Research, Ltd.Inventors: Mark R. Hellberg, Iok-Hou Pang
-
Patent number: 8546523Abstract: Disclosed are novel compounds having NPR-B agonistic activity. Preferred compounds are linear peptides containing 8-13 conventional or non-conventional L- or D-amino acid residues connected to one another via peptide bonds.Type: GrantFiled: September 23, 2010Date of Patent: October 1, 2013Assignee: Alcon Research, Ltd.Inventors: Frank Osterkamp, Heiko Hawlisch, Gerd Hummel, Tobias Knaute, Ulf Reimer, Ulrich Reineke, Uwe Richter, Bernadett Simon, Edgar Specker, Markus Woischnik, Mark R. Hellberg
-
Patent number: 8541364Abstract: The present invention is directed to the use of the peptide compound D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-L-threoninol as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilisate or liquid buffer solution or artificial mother milk formulation or mother milk substitute containing the peptide D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-L-threoninol optionally together with at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotectant, excipient and/or diluent.Type: GrantFiled: September 9, 2008Date of Patent: September 24, 2013Assignee: Mondobiotech Laboratories AGInventors: Dorian Bevec, Fabio Cavalli, Vera Cavalli, Gerald Bacher
-
Patent number: 8524674Abstract: Disclosed is a method of improving the conditioned reflex habit, the muscle tonus, or the motion coordination of a patient after suffering trauma to the brain cortex that involves administering to the patient an effective amount of a composition containing peptide glutamyl-aspartyl-arginine of the formula H-Glu-Asp-Arg-OH as its active base.Type: GrantFiled: August 15, 2012Date of Patent: September 3, 2013Assignee: Obschestvo S Ogranichennoi Otvetstvennostyu “Sia Peptides”Inventors: Vladimir Khatskelevich Khavinson, Evgeny Iosifovich Grigoriev, Vladimir Victorovich Malinin, Galina Anatolievna Ryzhak
-
Patent number: 8486380Abstract: Disclosed herein are multi-component formulations for enzymatically producing aqueous solutions of peroxycarboxylic acids suitable for use in, e.g., disinfectant and/or bleaching applications. The multi-component peroxycarboxylic acid formulations comprise at least one carbohydrate esterase family 7 enzyme having perhydrolytic activity.Type: GrantFiled: September 11, 2012Date of Patent: July 16, 2013Assignee: E. I. du Pont de Nemours and CompanyInventors: Robert Dicosimo, Arie Ben-Bassat, William R. Cahill, David George Dipietro, Eugenia Costa Hann, Mark S. Payne, Richard Alan Reynolds, Raymond Richard Zolandz
-
Patent number: 8450268Abstract: The present invention provides novel conformationally-defined macrocyclic compounds that have been demonstrated to be selective modulators of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as agonists of the ghrelin receptor and as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, central nervous system disorders, genetic disorders, hyperproliferative disorders and inflammatory disorders.Type: GrantFiled: December 11, 2008Date of Patent: May 28, 2013Assignee: Tranzyme Pharma Inc.Inventors: Graeme L. Fraser, Hamid R. Hoveyda, Mark L. Peterson